2009
DOI: 10.2353/jmoldx.2009.080106
|View full text |Cite
|
Sign up to set email alerts
|

Identification of Cystic Fibrosis Variants by Polymerase Chain Reaction/Oligonucleotide Ligation Assay

Abstract: The purpose of this work is to define rare variants of cystic fibrosis (CF) that are potential sources of error and can confound molecular genetic testing methods. We performed routine , clinical CF mutation screening using a laboratory-developed test and the oligonucleotide ligation assay reagents from Abbott/Celera. In this report, we describe 11 unique allele drop outs [3849 ؉ 10kb C>T (NM_000492.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
9
0

Year Published

2009
2009
2022
2022

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 9 publications
(9 citation statements)
references
References 8 publications
0
9
0
Order By: Relevance
“…There are many practical applications for the detection of ligated products, in addition to the detection of drug resistance-related point mutation, as demonstrated in this study [6].…”
Section: Discussionmentioning
confidence: 93%
See 1 more Smart Citation
“…There are many practical applications for the detection of ligated products, in addition to the detection of drug resistance-related point mutation, as demonstrated in this study [6].…”
Section: Discussionmentioning
confidence: 93%
“…A prominent mechanism used to determine the presence of point mutations is through DNA ligation at the position of the mutation [1,3,5,6]. DNA ligases facilitate the joining of nicks on doublestranded DNA duplexes.…”
Section: Introductionmentioning
confidence: 99%
“… CF: cystic fibrosis; IRT: immunoreactive trypsinogen; NBS: newborn screening. Complete sequencing of the CFTR gene 29 was performed in all patients, except patient 5, for whom a 32-mutation panel 25 was used. Variant nomenclature at complementary DNA; cDNA and protein levels is according to the reference sequences NM_000531.5 and NP_000522.3, respectively.…”
Section: Resultsmentioning
confidence: 99%
“…The remaining patient was analyzed against a panel of 32 pathogenic variants (Test Code 10458; Quest Diagnostics Nichols Institute, San Juan Capistrano, CA). 25 Previously unreported missense CFTR variants identified by sequencing were subjected to in silico analysis with the PolyPhen 26 , SIFT, 27 and MutationTaster 28 programs to predict their damaging effects.…”
Section: Methodsmentioning
confidence: 99%
“…The papers by Schwartz et al 14 and Hantash et al 15 fall under the "fine-tuning" category. As robust as the available multiplex testing platforms are, they are still subject to false results due primarily to interfering complexities of the CFTR sequence itself.…”
mentioning
confidence: 99%